Immunome, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
9.41 |
3.94 |
18.30 |
81.11 |
211.84 |
270.77 |
| Przychód Δ r/r |
0.00% |
-58.13% |
364.65% |
343.27% |
161.16% |
27.82% |
| Przychód (min) |
7.56 |
3.23 |
15.02 |
66.57 |
173.86 |
222.23 |
| Przychód (max) |
11.40 |
4.64 |
21.56 |
95.55 |
249.55 |
318.98 |
| EBITDA (średnia) |
1.88 |
0.79 |
3.66 |
16.22 |
42.37 |
54.15 |
| EBIT (średnia) |
1.88 |
0.79 |
3.66 |
16.22 |
42.37 |
54.15 |
| EBIT % |
20.00% |
20.00% |
20.00% |
20.00% |
20.00% |
20.00% |
| Zysk netto (średni) |
-258.12 |
-127.05 |
-129.59 |
-125.01 |
-46.72 |
-10.44 |
| Zysk netto % |
-2744.13% |
-3226.20% |
-708.19% |
-154.12% |
-22.05% |
-3.85% |
| EPS (średnia) |
-4.38 |
-2.17 |
-2.36 |
-2.08 |
-0.80 |
-0.18 |
| Liczba analityków (Przychody) |
6 |
5 |
8 |
7 |
4 |
3 |
| Liczba analityków (EPS) |
6 |
6 |
8 |
7 |
5 |
2 |
| symbol |
IMNM |
IMNM |
IMNM |
IMNM |
IMNM |
IMNM |